Joint Clinical Trials Office
A Two-Stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel with Placebo in the Treatment of Female Participants with Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2024
An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC Cell Therapy for the Treatment of Chronic Anal Fissure
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2024
A Study to Evaluate the Safety and Effectiveness of the Standard of Care Diversion, Diverting Ileostomy, Following Low Anterior Resection
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2024
Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: The PROMISE III Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 4, 2024
Technology dRiven Enhancement to Engage & Connect (TREE-Connect)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 10, 2024
Local Methotrexate Injections for the Treatment of Nail Psoriasis
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 12, 2024
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2024